Cost-Effectiveness of Targeted Prophylaxis among Allogenic Stem Cell Transplant Recipients
Nour Shbaklo(University of Turin), Francesco Giuseppe De Rosa(University of Turin), Irene Dogliotti(Unknown), Silvia Corcione(University of Turin), Alessandro Busca(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Carla Maria Zotti(University of Turin), Luisa Giaccone(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Costanza Vicentini(Department of Public Health), Chiara Maria Dellacasa(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Tommaso Lupia(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino)
Cited by 7
Related Papers
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study
|The Lancet Haematology|2020|553
Efficacy of Ceftazidime-Avibactam Salvage Therapy in Patients With Infections Caused by<i>Klebsiella pneumoniae</i>Carbapenemase–producing<i>K. pneumoniae</i>
|Clinical Infectious Diseases|2018|351
Genetic PTX3 Deficiency and Aspergillosis in Stem-Cell Transplantation
|New England Journal of Medicine|2014|301
Ceftazidime-Avibactam Use for Klebsiella pneumoniae Carbapenemase–Producing <i>K. pneumoniae</i> Infections: A Retrospective Observational Multicenter Study
|Clinical Infectious Diseases|2021|264
A pilot study of the Histone‐Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms
|British Journal of Haematology|2010|242